Gilead Sciences And Kite To Present 21 Abstracts, Including 5 Oral Presentations, Showcasing Kite's Continued Progress In Transforming Blood Cancer Care And Expanding Reach And Impact Of CAR T-Cell Therapy, At ASH 2025

– Updated Results from Phase 2 Pivotal iMMagine-1 Study of Anito-cel for Relapsed/Refractory Multiple Myeloma to be Presented Orally –

– New Findings Reinforce Yescarta's® Curative Potential as Second-Line Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma –

– Next-Generation CAR T-cell Therapies Suggest High Response Rates and Encouraging Durability in B-Cell Malignancies –

Gilead Sciences, Inc. (NASDAQ:GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (December 6-9). These data showcase Kite's continued progress in transforming blood cancer care and expanding the reach and impact of CAR T-cell therapy.